top of page

DMPK Resources

Links to some of my industry publications and Regulatory guidance(s): 

Approaches for Reducing Liability to Major Metabolically Driven Causes Of Drug Attrition: The Challenge To De-Risk Pharmaceuticals (Pharma Outsourcing)

De-Risking Drug Development (Medicine Maker)

The use of radiolabelled compounds in the investigation of Metabolism and Drug-Drug Interactions in vitro (PharmaChem, p2 onwards)

Drug Transporters: Emerging Technologies (PharmaChem, p13 onwards)

Useful Regulatory Guidance

Drug-Drug Interactions (DDI):

**New FDA DDI Draft Guidance, January 2020**

Current EMA (Europe) DDI Draft Guidance, July, 2012:

New PMDA (Japan) DDI Guidance - English Translation:

MIST:

**New FDA MIST Draft Guidance, March 2020**

EMA Guidance for Non-Clinical Studies to Enable Human Clinical Trials

IND/CTA guidance:

ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

FDA Guidance for Non-Clinical Studies to Enable Human Clinical Trials

bottom of page